Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bicalutamide - AstraZeneca

Drug Profile

Bicalutamide - AstraZeneca

Alternative Names: Casodex; Cosudex; ICI 176334; ICI176,334-1; Pencial

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA)
  • Class Anilides; Antiandrogens; Antineoplastics; Fluorinated hydrocarbons; Nitriles; Small molecules; Tosyl compounds
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Phase II Breast cancer
  • Discontinued Precocious puberty

Most Recent Events

  • 24 Jun 2021 AstraZeneca, Memorial Sloan Kettering Cancer Center and National Cancer Institute (NCI) complete a phase II trial in Breast cancer (Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT00468715)
  • 17 Feb 2021 Discontinued - Phase-II for Precocious puberty (Combination therapy, In adolescents, In children) in USA, Canada, France, India, Russia, United Kingdom (PO) (AstraZeneca pipeline, February 2021)
  • 20 Dec 2019 Anastrozole licensed to Juvise Pharmaceuticals for commercialisation in over 40 countries
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top